ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research ...

Fintel reports that on March 14, 2025, Jefferies initiated coverage of ANI Pharmaceuticals (NasdaqGM:ANIP) with a Buy ...

Fintel reports that on March 12, 2025, JP Morgan initiated coverage of ANI Pharmaceuticals (NasdaqGM:ANIP) with a Overweight ...

Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) had its price target lowered by Jefferies Financial Group from $70.00 to $53.00 in a research report report published on Tuesday,Benzinga reports.

Shift Biosciences, a biotech company using an AI powered virtual cell to fight age-related diseases, today announced the appointments of Jill Reckless, Ph.D, as Translation Advisor and Laurence Reid, ...

About $900 million in losses spread across two teams at hedge fund Millennium Management contributed to the firm’s worst monthly performance in over six years in February. Millennium lost 1.3% ...

MILLENNIUM Management lost about US$900 million so far this year from two teams focused on index rebalancing, a strategy recently upended by global stock market volatility, according to sources ...

(Bloomberg) -- Millennium Management lost about $900 million so far this year from two teams focused on index rebalancing, a strategy recently upended by global stock market volatility, according ...

JJ is an employee of Robarts Clinical Trials. BGF reports grant/research support from Millennium Pharmaceuticals, Merck, Tillotts Pharma AG, AbbVie, Novartis Pharmaceuticals, Centocor, Elan/Biogen, ...

Balkan’s FourSixThree Capital will start running $1 billion for Millennium in a separately managed account within a couple of weeks, according to a person with knowledge of the matter.

However, I think aggressive growth investors might want to consider buying Madrigal Pharmaceuticals' shares. Some analysts project that Rezdiffra could generate peak annual sales of close to $3.5 ...